Revance Therapeutics, Inc.
RVNCDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479290
Revance Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Feb 6, 2025; 174 institutions reported holding it in 13F filings for Q4 2024, worth $249.2M in total; Fairfax Financial was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 174
- Q4 2024, −26 vs. previous quarter
- 13F value
- $249.2M
- Reported value at the end of Q4 2024
- Superinvestors holding
- 1
- At the end of Q4 2024
Superinvestors holding RVNC, Q4 2024
1 superinvestor reports holding Revance Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Fairfax Financial
Prem Watsa
<0.1%
Revance Therapeutics, Inc.'s share of the portfolio
- Shares
- 21,158
- Value
- $64.1K
Latest insider trades
Open-market purchases and sales by Revance Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 (view filing) | Nov 18 | 1 day | Hollander DavidCMO & Global Therapeutics Lead | SSale | −3.91K | $4.17 | −$16.3K | −3.6%104.9K after | |
| Apr 17, 2024 (view filing) | Apr 16 | 1 day | Jordan EricaChief Commercial Officer | SSale | −2.39K | $3.80 | −$9.09K | −2.0%114.9K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Sjuts Dustin SPresident | SSale | −9.21K | $5.04 | −$46.4K | −5.2%167.6K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Moxie DwightCLO & GC | SSale | −8.13K | $5.04 | −$41.0K | −5.6%137.8K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Schilke TobinCFO | SSale | −9.36K | $5.04 | −$47.2K | −4.6%192.7K after | |
| Mar 8, 2024 (view filing) | Mar 6 | 2 days | Foley Mark JCEO | PPurchase | +30.0K | $6.98 | +$209.4K | +3.0%1.02M after | |
| Sep 7, 2023 (view filing) | Sep 5-6 | 2 days | Moxie DwightSVP, GC & Secretary | SSale | −34.9K | $17.57 | −$612.5K | −44.2%44.1K after | 2 lots10b5-1 |
| Aug 4, 2023 (view filing) | Aug 3 | 1 day | Foley Mark JCEO | SSale | −26.3K | $22.57 | −$593.1K | −3.0%840.4K after | 10b5-1 |
| Jul 5, 2023 (view filing) | Jul 3 | 2 days | Schilke TobinCFO | SSale | −1.70K | $25.04 | −$42.6K | −2.1%79.9K after | 10b5-1 |
| Jul 5, 2023 (view filing) | Jul 3 | 2 days | Foley Mark JCEO | SSale | −26.3K | $24.94 | −$655.4K | −2.9%866.7K after | 10b5-1 |
Top 10 13F holders, Q4 2024
The largest institutional positions in Revance Therapeutics, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,597,418 | $26.1M | 0.00% | −130,166−1.5% | Reduced |
| Beryl Capital Management LLC | 5,935,009 | $18.0M | 4.08% | +5,935,009 | New |
| Vanguard Group Inc | 5,625,091 | $17.1M | 0.00% | −108,608−1.9% | Reduced |
| Oddo BHF Asset Management SAS | 5,100,000 | $15.5M | 0.78% | +4,375,000+603.4% | Added |
| FIL Ltd | 4,196,095 | $12.8M | 0.01% | +3,162+0.1% | Added |
| Alliancebernstein L.P. | 3,497,112 | $10.6M | 0.00% | +236,641+7.3% | Added |
| Squarepoint Ops LLC | 3,164,943 | $9.62M | 0.02% | +855,281+37.0% | Added |
| Magnetar Financial LLC | 2,556,345 | $7.77M | 0.18% | +56,174+2.2% | Added |
| State Street Corp | 2,439,140 | $7.41M | 0.00% | +5,177+0.2% | Added |
| Alpine Associates Management Inc. | 2,349,966 | $7.14M | 0.43% | −1,812,895−43.5% | Reduced |